查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417538

ACE 抑制剂市场报告：2030 年趋势、预测与竞争分析

ACE Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

ACE抑制剂的趋势与预测

预计到 2030 年，全球 ACE 抑制剂市场将达到 60 亿美元，2024 年至 2030 年复合年增长率为 3.2%。该市场的主要驱动因素包括高血压相关疾病的增加、生物製药开发和生产的需求增加以及改善心血管疾病的研发活动活性化。全球ACE抑制剂市场的未来充满希望，心臟衰竭、高血压、慢性肾臟病和糖尿病市场充满机会。

ACE 抑制剂市场洞察

Lucintel 预测，由于对Lisinopril作为高血压治疗药物的需求增加以及Lisinopril的使用增加以提高心臟病发作后的生存率，Lisinopril在预测期内仍将是最大的细分市场。

由于对血管张力素转化酵素抑制剂的需求不断增加以及旨在改进抑制剂的研发业务不断扩大，预计北美在预测期内仍将是最大的地区。

常问问题

Q1.市场规模有多大？

A1. 到 2030 年，全球 ACE 抑制剂市场预计将达到 60 亿美元。

Q2.市场成长预测如何？

A2. 2024年至2030年，全球ACE抑制剂市场预计将以3.2%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素有哪些？

A3. 该市场的主要驱动因素是高血压相关疾病的增加、生物药品市场开拓和生产需求的增加以及改善心血管疾病的研发活动的增加。

Q4.市场的主要细分市场是什么？

A4.ACE抑制剂全球市场前景广阔，心臟衰竭、高血压、慢性肾臟病、糖尿病市场机会大。

Q5. 市场上主要企业有哪些？

A5. 生产 ACE 抑制剂的一些主要企业如下。

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计，在预测期内，Lisinopril仍将是其最大的细分市场，因为对赖诺普利作为治疗高血压的需求不断增长，并且越来越多地使用Lisinopril来提高心臟病发作后的生存率。我预测。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于对血管收缩素转化酵素抑制剂的需求增加以及旨在改进抑制剂的研究和开发的扩大，北美仍然是预测期内最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球ACE抑制剂市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球ACE抑制剂市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类型分類的全球 ACE 抑制剂市场
    • Lisinopril
    • Ramipril
    • Captopril
    • Moexipril
    • Fosinopril
    • Perindopril
    • 其他的
  • 全球 ACE 抑制剂市场（按应用）
    • 心臟衰竭
    • 高血压
    • 慢性肾臟病
    • 糖尿病
    • 其他的
  • 全球 ACE 抑制剂市场（依最终用途）
    • 医院
    • 药局
    • 网路药局
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球 ACE 抑制剂市场区域分布
  • 北美ACE抑制剂市场
  • 欧洲ACE抑制剂市场
  • 亚太ACE抑制剂市场
  • 其他地区ACE抑制剂市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按药物类型分類的全球 ACE 抑制剂市场成长机会
    • 全球 ACE 抑制剂市场成长机会（按应用）
    • 按最终用途分類的全球 ACE 抑制剂市场成长机会
    • 全球 ACE 抑制剂市场成长机会（按地区）
  • 全球ACE抑制剂市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球ACE抑制剂市场产能扩张
    • 全球ACE抑制剂市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company
简介目录

ACE Inhibitors Trends and Forecast

The future of the global ACE Inhibitors market looks promising with opportunities in the heart failure, hypertension, chronic kidney disease, and diabetes markets. The global ACE Inhibitors market is expected to reach an estimated $6.0 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising rates of hypertension-related diseases, rising demand for biopharmaceutical product development and production, as well as, growing number of research and development activities for the improvement of cardiovascular diseases.

A more than 150-page report is developed to help in your business decisions.

ACE Inhibitors by Segment

The study includes a forecast for the global ACE Inhibitors by drug type, application, end use, and region.

ACE Inhibitors Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lisinopril
  • Ramipril
  • Captopril
  • Moexipril
  • Fosinopril
  • Perindopril
  • Others

ACE Inhibitors Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Heart Failure
  • Hypertension
  • Chronic Kidney Disease
  • Diabetes
  • Others

ACE Inhibitors Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Pharmacies
  • Online Drug Stores
  • Others

ACE Inhibitors Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of ACE Inhibitors Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ACE Inhibitors companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ACE Inhibitors companies profiled in this report include-

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company

ACE Inhibitors Market Insights

Lucintel forecasts that lisinopril will remain the largest segment over the forecast period due to the growing demand for lisinopril medications for the treatment of high blood pressure, as well as a growth in the use of lisinopril to improve survival after a heart attack.

North America will remain the largest region over the forecast period because of the increased demand for angiotensin-converting enzyme inhibitors, as well as the expansion of research and development operations aimed at generating improved inhibitors.

Features of the Global ACE Inhibitors Market

Market Size Estimates: Ace inhibitors market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Ace inhibitors market size by drug type, application, end use, and region in terms of value ($B).

Regional Analysis: Ace inhibitors market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, application, end use, and regions for the ACE Inhibitors market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ACE Inhibitors market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the ACE Inhibitors market size?

Answer: The global ACE Inhibitors market is expected to reach an estimated $6.0 billion by 2030.

Q2. What is the growth forecast for ACE Inhibitors market?

Answer: The global ACE Inhibitors market is expected to grow with a CAGR of 3.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the ACE Inhibitors market?

Answer: The major drivers for this market are rising rates of hypertension-related diseases, rising demand for biopharmaceutical product development and production, as well as, growing number of research and development activities for the improvement of cardiovascular diseases.

Q4. What are the major segments for ACE Inhibitors market?

Answer: The future of the global ACE Inhibitors market looks promising with opportunities in the heart failure, hypertension, chronic kidney disease, and diabetes markets.

Q5. Who are the key ACE Inhibitors market companies?

Answer: Some of the key ACE Inhibitors companies are as follows.

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company

Q6. Which ACE Inhibitors market segment will be the largest in future?

Answer: Lucintel forecasts that lisinopril will remain the largest segment over the forecast period due to the growing demand for lisinopril medications for the treatment of high blood pressure, as well as a growth in the use of lisinopril to improve survival after a heart attack.

Q7. In ACE Inhibitors market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period because of the increased demand for angiotensin-converting enzyme inhibitors, as well as the expansion of research and development operations aimed at generating improved inhibitors.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the ACE Inhibitors market by drug type (lisinopril, ramipril, captopril, moexipril, fosinopril, perindopril, and others), application (heart failure, hypertension, chronic kidney disease, diabetes, and others), end use (hospitals, pharmacies, online drug stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global ACE Inhibitors Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global ACE Inhibitors Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global ACE Inhibitors Market by Drug Type
    • 3.3.1: Lisinopril
    • 3.3.2: Ramipril
    • 3.3.3: Captopril
    • 3.3.4: Moexipril
    • 3.3.5: Fosinopril
    • 3.3.6: Perindopril
    • 3.3.7: Others
  • 3.4: Global ACE Inhibitors Market by Application
    • 3.4.1: Heart Failure
    • 3.4.2: Hypertension
    • 3.4.3: Chronic Kidney Disease
    • 3.4.4: Diabetes
    • 3.4.5: Others
  • 3.5: Global ACE Inhibitors Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Pharmacies
    • 3.5.3: Online Drug Stores
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global ACE Inhibitors Market by Region
  • 4.2: North American ACE Inhibitors Market
    • 4.2.2: North American ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
  • 4.3: European ACE Inhibitors Market
    • 4.3.1: European ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
    • 4.3.2: European ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
  • 4.4: APAC ACE Inhibitors Market
    • 4.4.1: APAC ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
    • 4.4.2: APAC ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
  • 4.5: ROW ACE Inhibitors Market
    • 4.5.1: ROW ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
    • 4.5.2: ROW ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global ACE Inhibitors Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global ACE Inhibitors Market by Application
    • 6.1.3: Growth Opportunities for the Global ACE Inhibitors Market by End Use
    • 6.1.4: Growth Opportunities for the Global ACE Inhibitors Market by Region
  • 6.2: Emerging Trends in the Global ACE Inhibitors Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global ACE Inhibitors Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global ACE Inhibitors Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: AstraZeneca
  • 7.2: Abbott
  • 7.3: Bausch Health Companies
  • 7.4: Pfizer
  • 7.5: AbbVie
  • 7.6: Merck
  • 7.7: Novartis
  • 7.8: Johnson & Johnson
  • 7.9: Sanofi
  • 7.10: Eli Lilly and Company